Annexon (ANNX)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tan...
- Open
- 5.030
- High
- 5.308
- Low
- 5.020
- Prev. Close
- 5.130
- Volume
- 2.24M
- Turnover
- 11.76M
- Avg Price
- 5.242
- Bid/Ask Ratio
- 42.86%
- Amplitude
- 5.61%
- 52wk High
- 7.180
- Volume Ratio
- 0.90
- Turnover Ratio
- 1.37%
Annexon Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$14.71178.68%
Forecast & RatingBuy
10analysts
- Strong buy60.00%
- Buy20.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 03:06 PM
Annexon grants new hires options for 287,500 shares at $5.29 each
- TradingKey · 2 days ago, 03:02 AM
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track
- Simplywall · 2 days ago, 10:38 AM
Annexon (ANNX), Why Is The Market Paying Closer Attention?
- Simplywall · Aug 14 at 02:32 AM
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed
- PUBT · Aug 12 at 05:09 PM
Annexon files Form 3 as director Mark S. Blumenkranz reports no beneficial ownership
- TradingView · Aug 12 at 03:11 PM
Annexon, Inc. Q2 2026: Net loss $55.3M — 10-Q Summary
